[{"id":"9816c013-7051-40d1-84b8-45fdcad0628c","acronym":"","url":"https://clinicaltrials.gov/study/NCT03387553","created_at":"2021-01-18T16:43:05.859Z","updated_at":"2025-02-25T13:52:28.899Z","phase":"Phase 1","brief_title":"HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer","source_id_and_acronym":"NCT03387553","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" HER-2 • PGR • CD4","pipe":"","alterations":" ","tags":["HER-2 • PGR • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • docetaxel • Perjeta (pertuzumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 06/06/2018","start_date":" 06/06/2018","primary_txt":" Primary completion: 08/29/2026","primary_completion_date":" 08/29/2026","study_txt":" Completion: 08/29/2026","study_completion_date":" 08/29/2026","last_update_posted":"2025-02-14"},{"id":"cb5da6dd-a9b6-436a-acd6-01685f4f5bc2","acronym":"ETHAN","url":"https://clinicaltrials.gov/study/NCT05501704","created_at":"2022-08-15T12:10:47.553Z","updated_at":"2024-07-02T16:34:37.326Z","phase":"Phase 2","brief_title":"ETHAN - ET for Male BC","source_id_and_acronym":"NCT05501704 - ETHAN","lead_sponsor":"Jose Pablo Leone","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • anastrozole • Firmagon (degarelix) • Soltamox (tamoxifen citrate)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 10/11/2023","start_date":" 10/11/2023","primary_txt":" Primary completion: 04/01/2026","primary_completion_date":" 04/01/2026","study_txt":" Completion: 04/01/2036","study_completion_date":" 04/01/2036","last_update_posted":"2024-06-07"},{"id":"fb05cd3f-10d1-4b7d-9490-18dfc2923550","acronym":"","url":"https://clinicaltrials.gov/study/NCT05156606","created_at":"2021-12-14T12:53:37.114Z","updated_at":"2024-07-02T16:35:05.978Z","phase":"","brief_title":"Testosterone \u0026 Tamoxifen Trial","source_id_and_acronym":"NCT05156606","lead_sponsor":"University Medical Center Groningen","biomarkers":" HER-2 • CDK4","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 5","initiation":"Initiation: 11/10/2022","start_date":" 11/10/2022","primary_txt":" Primary completion: 10/03/2024","primary_completion_date":" 10/03/2024","study_txt":" Completion: 10/03/2024","study_completion_date":" 10/03/2024","last_update_posted":"2024-05-03"},{"id":"804c573f-8c22-4ca6-9bc7-e76c192b00c2","acronym":"","url":"https://clinicaltrials.gov/study/NCT02950259","created_at":"2021-01-18T14:29:26.884Z","updated_at":"2024-07-02T16:35:21.864Z","phase":"Phase 1","brief_title":"Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC)","source_id_and_acronym":"NCT02950259","lead_sponsor":"Providence Health \u0026 Services","biomarkers":" HER-2","pipe":" | ","alterations":" PD-L1 expression • HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • citoplurikin (IRX-2) • cyclophosphamide intravenous • omeprazole"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 02/09/2017","start_date":" 02/09/2017","primary_txt":" Primary completion: 05/13/2019","primary_completion_date":" 05/13/2019","study_txt":" Completion: 05/01/2024","study_completion_date":" 05/01/2024","last_update_posted":"2024-01-30"},{"id":"b6c67db8-9167-487d-b053-a4f146edce32","acronym":"GEICAM","url":"https://clinicaltrials.gov/study/NCT03800355","created_at":"2021-01-18T18:47:14.553Z","updated_at":"2024-07-02T16:35:22.288Z","phase":"","brief_title":"Study on the Progress of Breast Cancer Cases in Males and the Assessment of Relapse Risk","source_id_and_acronym":"NCT03800355 - GEICAM","lead_sponsor":"Spanish Breast Cancer Research Group","biomarkers":" HER-2 • BRCA","pipe":" | ","alterations":" HER-2 expression • BRCA mutation","tags":["HER-2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression • BRCA mutation"],"overall_status":"Completed","enrollment":" Enrollment 777","initiation":"Initiation: 09/14/2018","start_date":" 09/14/2018","primary_txt":" Primary completion: 03/31/2023","primary_completion_date":" 03/31/2023","study_txt":" Completion: 03/31/2023","study_completion_date":" 03/31/2023","last_update_posted":"2024-01-25"},{"id":"e6fd9872-8c2d-4670-ad4c-ac8cb8ebd070","acronym":"PePPy","url":"https://clinicaltrials.gov/study/NCT03018080","created_at":"2021-01-18T14:51:13.769Z","updated_at":"2025-02-25T16:05:42.198Z","phase":"Phase 2","brief_title":"Pilot Study of Paclitaxel Plus Pembrolizumab in Metastatic HER2-Negative Breast Cancer","source_id_and_acronym":"NCT03018080 - PePPy","lead_sponsor":"Wake Forest University Health Sciences","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative • HR positive + HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • paclitaxel"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 06/12/2017","start_date":" 06/12/2017","primary_txt":" Primary completion: 07/29/2021","primary_completion_date":" 07/29/2021","study_txt":" Completion: 08/05/2022","study_completion_date":" 08/05/2022","last_update_posted":"2023-08-04"},{"id":"e0aa1019-5c4c-4207-8e73-64bc03119d37","acronym":"MCC-18936","url":"https://clinicaltrials.gov/study/NCT03112590","created_at":"2021-01-18T15:20:06.945Z","updated_at":"2025-02-25T13:52:18.507Z","phase":"Phase 1/2","brief_title":"Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer","source_id_and_acronym":"NCT03112590 - MCC-18936","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HR positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Perjeta (pertuzumab) • albumin-bound paclitaxel • Actimmune (interferon gamma-1 b)"],"overall_status":"Completed","enrollment":" Enrollment 51","initiation":"Initiation: 06/23/2017","start_date":" 06/23/2017","primary_txt":" Primary completion: 03/31/2021","primary_completion_date":" 03/31/2021","study_txt":" Completion: 02/20/2023","study_completion_date":" 02/20/2023","last_update_posted":"2023-04-19"},{"id":"be3a087e-c43d-45b0-948c-231a7ba028c9","acronym":"","url":"https://clinicaltrials.gov/study/NCT02586675","created_at":"2021-01-18T12:32:56.266Z","updated_at":"2025-02-25T15:42:40.249Z","phase":"Phase 1","brief_title":"TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer","source_id_and_acronym":"NCT02586675","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 negative • PGR positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • Kisqali (ribociclib) • goserelin acetate"],"overall_status":"Completed","enrollment":" Enrollment 7","initiation":"Initiation: 02/23/2016","start_date":" 02/23/2016","primary_txt":" Primary completion: 05/08/2017","primary_completion_date":" 05/08/2017","study_txt":" Completion: 10/27/2021","study_completion_date":" 10/27/2021","last_update_posted":"2022-01-21"},{"id":"4ccc2c43-cf80-4471-8f20-ea4d38f5f9ef","acronym":"","url":"https://clinicaltrials.gov/study/NCT01037790","created_at":"2021-01-18T04:04:21.968Z","updated_at":"2024-07-02T16:36:33.413Z","phase":"Phase 2","brief_title":"Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer","source_id_and_acronym":"NCT01037790","lead_sponsor":"Abramson Cancer Center of the University of Pennsylvania","biomarkers":" HER-2 • KRAS • BRAF • ER • RB1 • CCND1 • CDK4 • CCND2","pipe":" | ","alterations":" KRAS mutation • ER positive • BRAF mutation • CCND1 amplification • CDK4 amplification • RB1 positive • CDK4 mutation","tags":["HER-2 • KRAS • BRAF • ER • RB1 • CCND1 • CDK4 • CCND2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • ER positive • BRAF mutation • CCND1 amplification • CDK4 amplification • RB1 positive • CDK4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Ibrance (palbociclib)"],"overall_status":"Completed","enrollment":" Enrollment 304","initiation":"Initiation: 10/01/2009","start_date":" 10/01/2009","primary_txt":" Primary completion: 10/01/2019","primary_completion_date":" 10/01/2019","study_txt":" Completion: 10/01/2019","study_completion_date":" 10/01/2019","last_update_posted":"2021-03-11"},{"id":"fd9fbd7f-ee3d-4043-9831-01acedf500b0","acronym":"","url":"https://clinicaltrials.gov/study/NCT00470301","created_at":"2021-01-18T01:40:22.121Z","updated_at":"2024-07-02T16:36:34.566Z","phase":"Phase 1/2","brief_title":"Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer","source_id_and_acronym":"NCT00470301","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 negative • PGR positive • PGR negative","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PGR positive • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • doxorubicin hydrochloride • cyclophosphamide • Zarnestra (tipifarnib) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 04/01/2007","start_date":" 04/01/2007","primary_txt":" Primary completion: 09/01/2013","primary_completion_date":" 09/01/2013","study_txt":" Completion: 09/01/2013","study_completion_date":" 09/01/2013","last_update_posted":"2021-02-16"},{"id":"f3a488ea-f6b4-4372-b29a-aef4d7a8f72c","acronym":"","url":"https://clinicaltrials.gov/study/NCT00343109","created_at":"2021-01-18T01:11:10.688Z","updated_at":"2024-07-02T16:36:50.140Z","phase":"Phase 2","brief_title":"Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer","source_id_and_acronym":"NCT00343109","lead_sponsor":"University of Washington","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression • HER-2 amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • AST-301 • Leukine (sargramostim)"],"overall_status":"Completed","enrollment":" Enrollment 38","initiation":"Initiation: 03/01/2004","start_date":" 03/01/2004","primary_txt":" Primary completion: 06/01/2015","primary_completion_date":" 06/01/2015","study_txt":"","study_completion_date":"","last_update_posted":"2020-02-12"},{"id":"7ec4dc43-23fc-4cf6-bad6-c9e36b3d162c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01355393","created_at":"2021-01-18T05:32:33.668Z","updated_at":"2024-07-02T16:36:50.276Z","phase":"Phase 1/2","brief_title":"Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast Cancer","source_id_and_acronym":"NCT01355393","lead_sponsor":"University of Washington","biomarkers":" HER-2 • CD4","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification","tags":["HER-2 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ampligen (rintatolimod) • HER-2/neu peptide vaccine • Leukine (sargramostim)"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 07/01/2011","start_date":" 07/01/2011","primary_txt":" Primary completion: 11/01/2013","primary_completion_date":" 11/01/2013","study_txt":"","study_completion_date":"","last_update_posted":"2020-02-10"},{"id":"2d7d4326-ad74-40fb-982a-d53615a7bd65","acronym":"","url":"https://clinicaltrials.gov/study/NCT01372579","created_at":"2021-01-18T05:37:22.994Z","updated_at":"2025-02-25T13:33:49.852Z","phase":"Phase 2","brief_title":"Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients","source_id_and_acronym":"NCT01372579","lead_sponsor":"Northwestern University","biomarkers":" EGFR • HER-2 • ER • PGR • CD44 • CD24 • ALDH1A1","pipe":" | ","alterations":" HER-2 negative • ER negative","tags":["EGFR • HER-2 • ER • PGR • CD44 • CD24 • ALDH1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Halaven (eribulin mesylate)"],"overall_status":"Unknown status","enrollment":" Enrollment 30","initiation":"Initiation: 08/01/2011","start_date":" 08/01/2011","primary_txt":" Primary completion: 06/01/2020","primary_completion_date":" 06/01/2020","study_txt":" Completion: 06/01/2021","study_completion_date":" 06/01/2021","last_update_posted":"2019-06-07"},{"id":"74bb0dc5-6670-4a97-bed0-b1c45b0dfe37","acronym":"CLARITY-01","url":"https://clinicaltrials.gov/study/NCT02580448","created_at":"2021-01-18T12:30:49.015Z","updated_at":"2024-07-02T16:37:03.253Z","phase":"Phase 1/2","brief_title":"CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448)","source_id_and_acronym":"NCT02580448 - CLARITY-01","lead_sponsor":"Innocrin Pharmaceutical","biomarkers":" HER-2 • ER","pipe":"","alterations":" ","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e seviteronel (INO-464)"],"overall_status":"Completed","enrollment":" Enrollment 175","initiation":"Initiation: 08/01/2015","start_date":" 08/01/2015","primary_txt":" Primary completion: 01/01/2019","primary_completion_date":" 01/01/2019","study_txt":" Completion: 01/01/2019","study_completion_date":" 01/01/2019","last_update_posted":"2019-02-01"},{"id":"fb13edff-4b83-43a6-a60f-ff80a6b3dba9","acronym":"","url":"https://clinicaltrials.gov/study/NCT01632332","created_at":"2021-01-18T07:00:51.975Z","updated_at":"2024-07-02T16:37:06.343Z","phase":"Phase 1","brief_title":"Vaccine Therapy in Treating Patients With Previously Treated Stage II-III HER2-Positive Breast Cancer","source_id_and_acronym":"NCT01632332","lead_sponsor":"Mayo Clinic","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 07/09/2012","start_date":" 07/09/2012","primary_txt":" Primary completion: 03/24/2014","primary_completion_date":" 03/24/2014","study_txt":" Completion: 07/09/2018","study_completion_date":" 07/09/2018","last_update_posted":"2018-10-09"},{"id":"368a0113-4719-4eb5-9c5b-b085f9138aa0","acronym":"","url":"https://clinicaltrials.gov/study/NCT02060253","created_at":"2021-01-18T09:29:26.595Z","updated_at":"2025-02-25T14:00:25.042Z","phase":"Phase 1","brief_title":"Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer","source_id_and_acronym":"NCT02060253","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" HER-2 • ER • PGR","pipe":"","alterations":" ","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • paclitaxel • Perjeta (pertuzumab) • ganetespib (ADX-1612)"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 04/01/2014","start_date":" 04/01/2014","primary_txt":" Primary completion: 06/01/2018","primary_completion_date":" 06/01/2018","study_txt":" Completion: 06/01/2018","study_completion_date":" 06/01/2018","last_update_posted":"2018-06-14"},{"id":"dc015bb2-1aa5-435a-b94b-ec2536465a7c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01928186","created_at":"2021-01-18T08:42:34.272Z","updated_at":"2024-07-02T16:37:10.762Z","phase":"","brief_title":"FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer","source_id_and_acronym":"NCT01928186","lead_sponsor":"University of Washington","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 09/01/2011","start_date":" 09/01/2011","primary_txt":" Primary completion: 07/20/2015","primary_completion_date":" 07/20/2015","study_txt":" Completion: 07/20/2015","study_completion_date":" 07/20/2015","last_update_posted":"2018-05-15"},{"id":"07bce700-fe42-4bb9-aa13-93f6cdc1621a","acronym":"","url":"https://clinicaltrials.gov/study/NCT01624441","created_at":"2021-01-18T06:58:11.122Z","updated_at":"2024-07-02T16:37:12.599Z","phase":"Phase 1","brief_title":"Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer","source_id_and_acronym":"NCT01624441","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PGR • MCL1","pipe":" | ","alterations":" HER-2 amplification • HER-2 negative","tags":["HER-2 • ER • PGR • MCL1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e epirubicin • dinaciclib (MK-7965)"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 08/21/2012","start_date":" 08/21/2012","primary_txt":" Primary completion: 09/10/2013","primary_completion_date":" 09/10/2013","study_txt":" Completion: 09/10/2013","study_completion_date":" 09/10/2013","last_update_posted":"2018-03-30"},{"id":"bdc04392-7fea-44b3-8c55-36b4fe355a8b","acronym":"","url":"https://clinicaltrials.gov/study/NCT01145430","created_at":"2021-01-18T04:33:29.572Z","updated_at":"2024-07-02T16:37:15.344Z","phase":"Phase 1","brief_title":"Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer","source_id_and_acronym":"NCT01145430","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PGR • BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["HER-2 • ER • PGR • BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e veliparib (ABT-888) • pegylated liposomal doxorubicin • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • doxorubicin liposomal"],"overall_status":"Completed","enrollment":" Enrollment 45","initiation":"Initiation: 06/01/2010","start_date":" 06/01/2010","primary_txt":" Primary completion: 05/23/2017","primary_completion_date":" 05/23/2017","study_txt":"","study_completion_date":"","last_update_posted":"2017-12-22"},{"id":"13fed650-f60f-454c-9a8a-c01f77da9c87","acronym":"","url":"https://clinicaltrials.gov/study/NCT00118157","created_at":"2021-01-18T00:23:49.573Z","updated_at":"2024-07-02T16:37:15.886Z","phase":"Phase 2","brief_title":"Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen","source_id_and_acronym":"NCT00118157","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • HER-2 • PGR","pipe":" | ","alterations":" PGR positive","tags":["EGFR • HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lapatinib • Soltamox (tamoxifen citrate)"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 05/01/2005","start_date":" 05/01/2005","primary_txt":" Primary completion: 07/01/2011","primary_completion_date":" 07/01/2011","study_txt":" Completion: 09/01/2014","study_completion_date":" 09/01/2014","last_update_posted":"2017-12-04"},{"id":"093ed07b-b9c6-441a-9a95-1831c85191b9","acronym":"","url":"https://clinicaltrials.gov/study/NCT01104259","created_at":"2021-01-18T04:22:11.005Z","updated_at":"2024-07-02T16:37:18.990Z","phase":"Phase 1","brief_title":"Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer","source_id_and_acronym":"NCT01104259","lead_sponsor":"University of Washington","biomarkers":" HER-2 • ER • PGR • BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["HER-2 • ER • PGR • BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • veliparib (ABT-888) • vinorelbine tartrate"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 07/01/2010","start_date":" 07/01/2010","primary_txt":" Primary completion: 02/01/2015","primary_completion_date":" 02/01/2015","study_txt":" Completion: 04/01/2017","study_completion_date":" 04/01/2017","last_update_posted":"2017-08-10"},{"id":"8530259c-2cd9-436f-a35f-dd9297f37048","acronym":"","url":"https://clinicaltrials.gov/study/NCT00003199","created_at":"2021-01-17T22:50:23.308Z","updated_at":"2024-07-02T16:37:20.031Z","phase":"Phase 2","brief_title":"Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer","source_id_and_acronym":"NCT00003199","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" CD34 • IL2 • CSF2","pipe":"","alterations":" ","tags":["CD34 • IL2 • CSF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • melphalan • thiotepa • Proleukin (aldesleukin) • busulfan • Leukine (sargramostim) • Soltamox (tamoxifen citrate)"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 11/01/1997","start_date":" 11/01/1997","primary_txt":" Primary completion: 12/01/2009","primary_completion_date":" 12/01/2009","study_txt":" Completion: 12/01/2009","study_completion_date":" 12/01/2009","last_update_posted":"2017-07-12"},{"id":"495cb1bd-cd29-44f5-9be4-e00fda829d84","acronym":"","url":"https://clinicaltrials.gov/study/NCT00791037","created_at":"2021-01-18T03:00:07.455Z","updated_at":"2024-07-02T16:37:21.728Z","phase":"Phase 1/2","brief_title":"Vaccine Therapy in Treating Patients With Stage IV Breast Cancer","source_id_and_acronym":"NCT00791037","lead_sponsor":"University of Washington","biomarkers":" HER-2 • IFNG • CD4","pipe":" | ","alterations":" HER-2 overexpression • HER-2 amplification","tags":["HER-2 • IFNG • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • HER-2/neu peptide vaccine • Leukine (sargramostim) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 23","initiation":"Initiation: 10/01/2008","start_date":" 10/01/2008","primary_txt":" Primary completion: 07/01/2013","primary_completion_date":" 07/01/2013","study_txt":" Completion: 12/01/2014","study_completion_date":" 12/01/2014","last_update_posted":"2017-05-25"},{"id":"d057f56b-f783-458b-9509-43b66fe279f0","acronym":"","url":"https://clinicaltrials.gov/study/NCT01658969","created_at":"2021-03-29T21:52:20.526Z","updated_at":"2024-07-02T16:37:27.186Z","phase":"Phase 2","brief_title":"Laboratory Treated T Cells After Chemotherapy in Treating Patients With HER2-Negative Stage II-III Breast Cancer That Can Be Removed By Surgery","source_id_and_acronym":"NCT01658969","lead_sponsor":"Barbara Ann Karmanos Cancer Institute","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 amplification • HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • docetaxel • doxorubicin hydrochloride • cyclophosphamide • Undisclosed HER2Bi-armed ATC • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 07/01/2010","start_date":" 07/01/2010","primary_txt":" Primary completion: 06/01/2015","primary_completion_date":" 06/01/2015","study_txt":" Completion: 11/01/2015","study_completion_date":" 11/01/2015","last_update_posted":"2016-12-07"}]